title: Liver transplantation for malignancies.
abstract: Liver transplantation (LT) has become an acceptable and effective treatment for selected patients with hepatocellular carcinoma with excellent outcomes. More recently, LT has been tried in different primary and secondary malignancies of the liver. The outcomes of LT for very selected group of patients with hilar cholangiocarcinoma (CCA) have been promising. Excellent results have been reported in LT for patients with unresectable hepatic epithelioid hemangioendothelioma (HEHE). In contrast to excellent results after LT for HEHE, results of LT for angiosarcoma have been disappointing with no long-term survivors. Hepatoblastoma (HB) is the most common primary liver cancer in pediatric age group. Long-term outcomes after LT in patients with unresectable tumor and good response to chemotherapy have been promising. Indication for LT for hepatic metastasis from neuroendocrine tumors (NETs) is mainly for patients with unresectable tumors and for palliation of medically uncontrollable symptoms. Posttransplant survival in those patients with low tumor activity index is excellent, despite recurrence of the tumor. More recent limited outcomes data on LT for unresectable hepatic metastases from colorectal cancer have claimed some survival benefit compared to the previous reports. However, due to the high rate of tumor recurrence in a very short time after LT, especially in the era of organ shortage, this indication has not been favored by the transplant community.
authors.affiliation: Hepato-pancreato-biliary/Liver Transplant Surgery, Cleveland Clinic, Desk A-100, 9500 Euclid Avenue, Cleveland, OH, 44195, USA, eghtesb@ccf.org.
authors.forename: Bijan
authors.initials: B
authors.lastname: Eghtesad
authors.forename: Federico
authors.initials: F
authors.lastname: Aucejo
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000601:surgery; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000601:surgery; D001653:Bile Ducts, Intrahepatic / Q000601:surgery; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D059248:Chemoradiotherapy; D018281:Cholangiocarcinoma / Q000601:surgery / Q000628:therapy; D015179:Colorectal Neoplasms; D003131:Combined Modality Therapy; D000075202:Contraindications; D018323:Hemangioendothelioma, Epithelioid / Q000601:surgery; D006394:Hemangiosarcoma / Q000601:surgery; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D016031:Liver Transplantation / Q000706:statistics & numerical data; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D018358:Neuroendocrine Tumors / Q000556:secondary / Q000601:surgery; D018579:Patient Selection; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents